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INSURANCE COVERAGE FOR CANCER TREATMENTINDUCED CONDITIONS: COMPARING FERTILITY
PRESERVATION TECHNOLOGY AND BREAST
RECONSTRUCTIVE SURGERY
Lisa Campo-Engelstein*

I.

INTRODUCTION

There is much debate not only about the morality of assisted reproductive technologies (ART), but also about how they should be classified. Should ART be understood as medical treatment for a disease
(infertility), or should these technologies be relegated to boutique
medicine where they are seen as elective? How we answer this question affects our thoughts about whether ART should be covered by
insurance companies. Those who claim infertility is a medical disease
usually advocate that ART be covered by insurance. Conversely,
those who believe ART are elective procedures generally oppose insurance coverage, insisting that insurance coverage should be limited
to medically necessary treatments. While the debate cannot simply be
reduced to whether "real" diseases should be covered by insurance
and all other conditions should not, in the minds of many, a strong
connection exists between what is considered a disease and what insurance should cover. For the purposes of this Commentary, therefore, the belief that medically necessary procedures should be covered
by insurance-whereas elective procedures should not-will serve as
the basis of the discussion.
Most discussions of ART focus on their use in two circumstances.
The first is to treat people currently suffering from infertility due to
disease (such as endometriosis) or some unknown cause. The second,
and more recent, is to provide "insurance" against age-related infertil* Assistant Professor, Alden March Bioethics Institute & Department of OBGYN, Albany
Medical College. The author would like to thank Sarah Rodriguez and Teresa Woodruff for
their feedback and support. This research was supported by the Oncofertility Consortium NIH
8UL1DE019587, 5RL1HDO58296. Earlier versions of this Commentary were published in Lisa
Campo-Engelstein, Consistency in Insurance Coverage for latrogenic Conditions Resultingfrom
Cancer Treatment Including Fertility Preservation, 28 J. CLINICAL ONCOLOGY 1284 (2010), and
Lisa Campo-Engelstein, For the Sake of Consistency and Fairness: Why Insurance Companies
Should Cover latrogenic Infertility, in ONCOFERTILITY: ETHICAL, LEGAL, SOCIAL, AND MEDICAL
PERSPECTIvEs 381 (Teresa K. Woodruff, Laurie Zoloth, Lisa Campo-Engelstein & Sarah Rodriguez eds., 2010).
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ity for women who plan to delay childbearing. Though still a contentious issue, the former-disease-induced infertility-is typically
thought to be more deserving of insurance coverage than the latterage-related infertility-because the cause of infertility is a disease, a
"legitimate" medical problem rather than an individual's conscious
decision. Indeed, some have argued that insurance should cover treatment for the underlying disease that is causing infertility (such as open
a blocked fallopian tube) even if they do not think insurance should
cover ART.1 The perceived cause of age-related infertility is, in contrast, not often seen as legitimate, but rather as the result of a
woman's choices and selfishness. According to this view, a woman's
desire to have a career leads her to delay childbearing, which is no
one's fault but her own. 2 In short, age-related infertility is not a medical problem and thus should not be covered by insurance.
Although this Commentary centers on infertility and insurance coverage, it diverges from these other debates in two significant ways.
First, it will bypass the question of whether infertility should be classified as a disease. Second, it does not deal with disease-induced or agerelated infertility. Rather, it focuses on another circumstance in which
one might use ART: before undergoing necessary medical treatment
that may lead to infertility. Specifically, I am concerned with fertility
preservation procedures for cancer patients who are about to receive
chemotherapy or radiation, both of which often cause infertility. I will
refer to this type of infertility as iatrogenic infertility.
II.

INSURANCE COVERAGE FOR

IATROGENIC

CONDITIONS

An iatrogenic condition is a negative side effect or adverse condition that is caused by the diagnosis, manner, activity, or treatment of a
health care provider. I recognize that this is a loaded term (which
insurance companies and providers typically prefer not to use), in part
because some see it as a normative term implying a provider's wrongdoing and blame. While this term encompasses negligent iatrogenic
conditions, such as a surgeon leaving a scalpel inside the body of a
patient, this Commentary uses it to refer only to nonnegligent conditions. Nonnegligent iatrogenic conditions occur when medically necessary treatments have unavoidable or unpredictable negative side
effects, such as cancer treatment causing infertility, hair loss, or nausea. Health care providers are not to blame in these situations, as they
1. Interview with Marybeth Gerrity, Director of the Oncofertility Consortium, Northwestern
Univ., in Chi., Ill. (June 2009).
2. See generally Imogen Goold & Julian Savulescu, In Favourof Freezing Eggs for Non-Medical Reasons, 23 BIOETHics 47 (2008) (discussing and arguing against this position).
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face a no-win situation: providers must harm their patients in order to
treat and hopefully save these patients' lives. Unfortunately, the nature of certain cancer treatments, as well as various treatments for
other diseases, is inherently harmful (for example, it destroys healthy
cells along with cancerous ones).
Insurance companies generally cover treatment for iatrogenic conditions that result from cancer treatment even though they do not
cover these same conditions when they are "naturally" occurring.
Infertility treatment, on the other hand, is typically not covered, regardless of whether it is iatrogenic or naturally occurring. One reason
many insurance companies refuse to cover ART is that they are often
viewed as elective procedures, not medically necessary ones. However, based on insurance coverage patterns for other "elective" procedures performed in response to iatrogenic conditions, insurance
companies should also cover ART, specifically fertility preservation
treatments (such as cryopreservation of eggs, embryos, or ovarian tissue for later use) for female cancer patients. In this way, insurance
companies will maintain consistency and promote fairness because
fertility preservation does not differ significantly from other treatments for iatrogenic conditions they already cover for women. While
my focus is on female fertility preservation, one could presumably
make a similar argument that male fertility preservation should be
covered by insurance.
In order to support this claim, I compare ART for iatrogenic infertility to breast reconstruction surgery. When following a lumpectomy
or mastectomy, breast reconstruction is generally covered by insurance. Just as in the case of infertility, there is probably not agreement
on whether breast construction surgery for women who naturally have
only one breast is medically necessary or elective. While having only
one breast is rarely (if ever) a naturally occurring condition, this comparison makes for a good thought experiment. I will briefly explore
the different ways of understanding and classifying this condition to
highlight the discord.
Most would agree that missing a breast is not a life-threatening situation. However, it would probably adversely affect a woman's quality
of life. For example, surveys have shown that the loss of a breast
makes women feel less feminine-that is, less of a "real" woman 3 and I imagine women born without a breast would have similar emotions. Moreover, women without two breasts may also make others
3. See Demetris Stavrou et al., Quality of Life After Breast Cancer Surgery with or Without
Reconstruction, EPLASTY, 161, 164 (June 2, 2009), availableat http://www.eplasty.com/index.php?
option=comcontent&view=article&id=294&catid=170:volume-09-eplasty-2009&Itemid=121.
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feel uncomfortable because these women do not have all the typical
feminine gender markers (for example, gender markers include
breasts, hips, long(er) hair, and a lack of facial hair). Indeed, the
social response to women with one or no breasts may mimic the social
response to people who are intersex, as their physical appearance does
not match the "normal" female or male body. Yet, some have argued
that the condition of intersex is largely a social-not a medical-problem because it generally does not cause any physical health problems
and instead causes strong cultural discomfort by blurring and confusing the gender lines.4 Likewise, one could claim having only one
breast does not lead to physical health problems, only personal and
cultural angst; thus, it should not be understood as a disease in need of
surgery.
Those who support a narrow, scientific definition of disease based
on biological functioning may also agree that having only one breast
does not require treatment and may assert that this condition is just an
anomaly like six fingers. Objectivist perspectives on disease echo this
belief, insisting that not all anomalies are diseases: "to call something
a disease involves both a claim about the abnormal functioning of
some bodily system and a judgment that the resulting abnormality is a
bad one." 5 According to this view, classifying a condition as a disease
is a normative claim, so determining whether having one breast is a
medical condition involves drawing on one's own subjective values
and judgments. Some may concur that having one breast engenders
social problems, not physical health problems, yet still view this condition as a disease in need of treatment. This claim relies on a broad
definition of health like the one used by the World Health Organization: "Health is a state of complete physical, mental and social wellbeing and not merely the absence of disease or infirmity." 6 Under
such a definition, having only one breast would be considered a condition that interferes with one's social and mental health and quality of
life. Consequently, it should receive treatment.
The above discussion shows that there is not consensus regarding
whether surgery for women who naturally have only one breast is
medically necessary or elective. The same is true for ART to treat
infertility; there is little agreement on whether these procedures are
4. See Alice Domurat Dreger, "Ambiguous Sex"-or Ambivalent Medicine? EthicalIssues in
the Treatment of Intersexuality, HASTINGS CENTER REP., May-June 1998, at 24, 27, 30.
5. Dominic Murphy, Concepts of Disease and Health, STAN. ENCYCLOPEDIA PHIL. (2008),
http://plato.stanford.edularchives/sum2009/entries/health-disease.
6. WORLD HEALTH ORG., BASIC DOCUMENTS 1 (47th ed. 2009) (Constitution of the World
Health Organization).
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medically necessary or elective. This similarity is important because,
while breast surgery is covered by insurance when iatrogenic, it is unlikely that all insurance companies would cover this surgery when it is
naturally occurring. As such, even though ART are often not covered
due to differences in how infertility is understood and classified, insurance companies should cover ART in cases of iatrogenic infertility because it promotes consistency and fairness.
However, the case for insurance coverage for iatrogenic infertility
using the above comparison may remain unconvincing due to the infrequency of women having only one breast. A more common condition for which there would probably be greater consensus about its
treatment as elective is asymmetrical breasts. While having only one
breast is rarely a naturally occurring condition, naturally occurring
breast asymmetry is quite common. Insurance companies rarely cover
surgery for naturally occurring asymmetrical breasts, and I imagine
most people would agree with this decision. Breast asymmetry is
rarely as conspicuous or socially isolating as having only one breast, so
it makes sense that it would rank lower on the list of conditions that
should be covered by insurance. Indeed, surgery to "remedy" breast
asymmetry is often put on par with other "purely" cosmetic procedures, such as otoplasty for "protruding" ears and rhinoplasty for
"6overly large" or "overly wide" noses. In sum, while these procedures
can improve an individual's self-esteem and thus quality of life, they
are generally seen as elective.
While surgery for naturally occurring breast asymmetry is not generally covered by insurance companies, surgery to resolve breast
asymmetry that results from a lumpectomy is usually covered, implying that the procedure is medically necessary. Moreover, in the case
of iatrogenic breast asymmetry, this surgery is covered regardless of
whether the patient had symmetrical breasts beforehand. Likewise,
breast reconstruction surgery following a mastectomy is typically covered, despite the debate over whether breast construction surgery
should be covered for naturally occurring "missing" breasts.
The discrepancy in breast surgery coverage between iatrogenic and
naturally occurring conditions can be explained, at least in part, by
looking at causality. According to one view, iatrogenic conditions are
caused by the medical realm and therefore the medical realm-specifically the insurance companies-should take financial responsibility
for alleviating or fixing them. In other words, because members of the
medical profession caused the harm-something they are not supposed to do-the medical profession as a whole must take responsibil-
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ity for mitigating the harm. 7 The same principles apply when
naturally occurring conditions are thought to be caused by bad luck
or, at times, by the individual herself. Since the medical realm is not
causally responsible for these naturally occurring conditions, one
could argue that they should not be financially responsible for them.
At play in this connection between causality and responsibility is the
static understanding of the body that dominates medicine and science.
Briefly, this is the idea that the body stays the same over time and that
disease is an aberration that must be eradicated to restore the body to
its "natural" and "normal" state. If any alterations occur in the process of healing the body, health care providers should do their best to
fix them so that the person's body is as close as possible to her original
state when they are finished.
Congress passed certain laws to institutionalize the medical realm's
responsibility for iatrogenic harms. For instance, the Women's Health
and Cancer Rights Act, passed in 1998, mandates that health insurance companies covering the costs of mastectomies for cancer patients
must also cover the costs of breast reconstruction for those patients.8
Health care providers and insurance companies sometimes assume responsibility for iatrogenic harms by the way they code for billing. For
example, breast reconstruction surgery following a mastectomy is
coded as cancer treatment rather than elective treatment. By allowing
treatments for iatrogenic conditions to be subsumed into the larger
category of disease treatment, insurance companies are tacitly accepting financial responsibility to cover these treatments. In addition
to breast reconstruction surgery, there are other treatments that may
not be covered by insurance when the disease is naturally occurring
(in part because treatment is not seen as medically necessary), but are
covered when iatrogenic; for example, wigs following cancer treatment are usually covered, whereas wigs for thinning hair or "cosmetic" reasons often are not.
The same pattern of insurance coverage seems to exist, though
more covertly, in the fertility and infertility realms. Although fifteen
states now have laws mandating that insurance companies cover infer-

7. The idea that the medical profession should take responsibility for any harm it engenders
dates back to the Hippocratic Oath. Today, this idea is implemented through insurance coverage
for iatrogenic conditions.
8. See Women's Health and Cancer Rights Act of 1998, Pub. L. No. 105-277, 112 Stat. 2681337 (codified at 29 U.S.C. § 1185b); see also U.S. DEPT OF LABOR, Your Rights After a Mastectomy: Women's Health and Cancer Rights Act of 1998 (2009), http://www.dol.gov/ebsa/publications/whcra.html.
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tility treatment under certain circumstances, 9 many insurance companies refuse to cover naturally occurring infertility or fertility
preservation treatments. Insurance companies give multiple reasons
why ART should not be covered: infertility treatments are experimental; they do not treat an underlying disease, but rather produce a desired outcome (a child); and they are an elective, not a medical,
procedure. 10 However, there is growing evidence that insurance companies are covering iatrogenic infertility resulting from cancer treatment." Although no formal studies have been done, anecdotal data
demonstrate that insurance companies will sometimes take financial
responsibility for iatrogenic infertility.
At the Oncofertility Consortium, female cancer patients have the
option to choose a fertility preservation method-embryo, egg, or
ovarian tissue cryopreservation-before beginning cancer treatment.
These fertility preservation treatments have been billed under a primary diagnosis of cancer and a secondary diagnosis of procreative
management. Although there have been many appeals and much negotiation, so far insurance companies have covered many of these
treatments for the Consortium's patients. Fertile Hope, a nonprofit
organization that provides reproductive information and support to
cancer patients and survivors, also notes that some cancer patients
have convinced their insurance companies to cover fertility preservation by noting that insurance companies cover side effects of all other
medically necessary cancer treatments and that infertility should not
be different.12

III. FIVE OBJECTIONS TO INSURANCE COVERAGE OF
IATROGENIC INFERTILITY
The trend toward covering ART for cancer patients with iatrogenic
infertility is a move in the right direction, as it creates consistency in
policy coverage instead of treating infertility differently than other ia-

trogenic conditions. However, some may argue that insurance companies should not cover these treatments because they differ in
significant ways from treatments for other iatrogenic conditions. The
9. Gwendolyn P. Quinn et al., State Laws and Regulations Addressing Third-Party Reimbursement for Infertility Treatment: Implicationsfor Cancer Survivors, 95 FERTILITY & STERILITY 72,
75 (2011).
10. See Note, In Vitro Fertilization:Insurance and Consumer Protection, 109 HARv. L. REV.
2092, 2096-97 (1996).
11. Interview with Kristin Smith, Fertility Preservation Patient Navigator, Oncofertility Consortium. Northwestern Univ., in Chi., Ill. (Sept. 2011).
12. See FinancialAssistance, FERTILE HOPE, http://www.fertilehope.org/financial-assistance/
index.cfm (last visited Feb. 15, 2012).
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following discussion will raise and respond to five objections to insurance coverage of iatrogenic infertility.
First, some ART, particularly egg and ovarian tissue cryopreservation, are considered experimental procedures, whereas breast reconstruction surgery is an established procedure. By practice, insurance
companies rarely cover experimental procedures. Although the
American Society for Reproductive Medicine still defines egg cryopreservation as experimental,13 this technology, especially egg freezing using vitrification, is improving rapidly, and some in the scientific
community no longer view it as experimental.14 Additionally, egg and
ovarian tissue cryopreservation are the only available options for
young or single women to be able to have a child with a future partner, not a sperm donor. Creating embryos, the only "mature" technology, runs the risk that the biological father could oppose transfer.
As a matter of social justice, fertility preservation options not requiring sperm need to be available to women in order to ensure they will
be able to have a biological child and have that child with the man
they choose.
Second, insurance companies tend to cover iatrogenic conditions
that currently exist, like hair loss from chemotherapy, or that will almost certainly exist, like loss of an entire breast following a mastectomy. Insurance companies do not traditionally cover conditions that
may or may not exist in the future, like infertility. Yet, a low
probability of occurrence should not lead providers to forgo prophylactic procedures to avoid iatrogenic conditions. In fact, providers
typically provide treatments to prevent iatrogenic conditions that may
or may not occur, such as antiemetics for nausea and dental evaluations for osteoradionecrosis. Health care providers often recommend
storing one's own blood as a prophylactic precaution in the case of an
emergency transfusion. Whether the stored blood will be used cannot
be predicted, but patients often want to be prepared for possible
"worst-case scenarios." Those who seek fertility preservation treatment are similarly motivated as those who store blood: in one worstcase scenario-where patients find themselves infertile after cancer
treatment-these patients have a reserve of gametes to use to have
biological children.
13. Age and Elective Egg Freezing: The Allure of Postponing ChildbearingWaxes as Odds of a
Successful Outcome Wane, AM. Soc'Y FOR REPROD. MED. (Oct. 18, 2011), http://www.asrm.org/
news/article.aspx?id=7336&terms=(+%40Publish To+Both+Sites+or+%40Publish To+ASRM+
Only+)+and+age+and+elective.
14. See Mitch Leslie, Melting Opposition to Frozen Eggs, SCIENCE, Apr. 2007, at 388.
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While treatment for most iatrogenic conditions generally occurs
very soon or immediately after cancer treatment, in the case of fertility preservation, frozen embryos, eggs, and ovarian tissue may not be
used for many years, even decades. However, according to the principle of moral neutrality, the timing of a harm has no moral significance.1 5 Consequently, the time at which a woman experiences the
harm of iatrogenic infertility-whether it is six months or six years
following treatment-does not change the degree of harm. Furthermore, some iatrogenic conditions do not materialize immediately, but
rather take time to develop (for example, stomach ulcers from
ibuprofen).
Third, when insurance companies cover iatrogenic conditions that
would not be covered when naturally occurring (such as breast surgery and wigs), part of the reason for doing so is that the results of the
treatment, which are visible to both the patient and others, normalizes
the patient's gendered body and identity. Women without certain
gender markers, like breasts or head hair, often feel less feminine,
which affects their sense of self and quality of life. Moreover, others
in society may feel uncomfortable with, and act differently toward, a
woman whose physical appearance does not match the "normal"
female body. Yet, fertility preservation treatment also normalizes
women's gendered body and identity in a visible way. In addition to
the fact that motherhood is an important part of many women's identity, there is a social expectation that women have children. Pregnancy is one of the most visible symbols of femininity, as is a woman
caring for children.
Fourth, fertility preservation treatment is inherently more socially
and ethically complex because it not only affects the individual patient, but also involves and impacts her current or future partner, her
family (including her parents and current children), and future offspring in ways that treatment for other iatrogenic conditions do not.
While fertility preservation treatment is indeed more socially and ethically complex than other treatments, this difference is not pertinent to
discussions of insurance coverage. Insurance companies often cover
socially and ethically complex procedures outside of ART, including
"corrective" surgery for intersex infants, fetal surgery, and genetic
testing for hereditary diseases. The social and ethical complexity of
the treatment should not factor into coverage decisions, though it may
indicate that patients need extra counseling before making treatment
decisions.
15.

JOHN RAWLS,

A

THEORY OF JUSTICE

403-04 (1971).
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Unlike the first four objections, the last objection does not compare
ART with other covered treatments. Rather, it deals with the appropriateness of providing ART to cancer patients because cancer patients do not meet the definition of infertility. When insurance
companies do cover infertility treatment, it generally only applies to
those diagnosed as infertile, commonly defined as the inability to conceive after one year of regular and unprotected heterosexual intercourse. Although cancer patients are not infertile at the time when
fertility preservation treatment would take place (right before the
commencement of cancer treatment), for many, infertility is an unfortunate inevitability following some treatments. While it is difficult to
precisely predict a patient's chance of infertility, some treatments generally yield infertility rates of eighty percent or more. 16 Although it is
true that cancer patients do not fit the standard definition of infertility, this does not mean that their need for infertility treatment is any
less-in some ways, their need for infertility treatment is greater. Unlike traditional infertility patients who can continue receiving infertility treatment until they conceive, cancer patients often only have one
opportunity to preserve their fertility because preservation must occur
before they begin cancer treatment. The unique situation cancer patients face reveals the traditional definition of infertility as too limited,
for it cannot account for the fertility preservation needs of those with
foreseeable iatrogenic infertility.
IV.

CONCLUSION

As the field of oncofertility continues to develop and fertility preservation options continue to expand, insurance companies will increasingly be confronted with how to handle iatrogenic infertility for
cancer patients. I have argued that ART for cancer patients are similar to treatments for other iatrogenic conditions that are currently
covered by insurance and thus their exclusion from insurance coverage is unjustified. Insurance companies should, for the sake of consistency and fairness, cover fertility preservation treatment for cancer
patients. Given the controversy surrounding reproductive technologies, this suggestion may be met with fierce opposition. However, it is
time for insurance companies to stop relegating ART to a separate
realm outside of "real" health care, especially when they cover treatment for conditions that could also be perceived as elective. The fact
that insurance companies have begun covering fertility preservation
16. See Stephanie J. Lee et al., American Society of Clinical Oncology Recommendations on
Fertility Preservation in Cancer Patients, 24 J. CLINICAL ONCOLOGY 2917, 2919 tbl.2 (2006).
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treatment for cancer patients gives hope that fertility and infertility
treatments are finally being taken seriously by insurance companies.
Nevertheless, this coverage is done covertly on a case-by-case basis
rather than under a blanket policy, which insinuates that insurance
companies are still not ready to publicly assume financial responsibility for iatrogenic infertility.
Perhaps a state or federal mandate, modeled after the Women's
Health and Cancer Rights Act, is necessary for insurance companies
to begin openly and universally covering treatment for iatrogenic infertility. Such a mandate would not only symbolize the importance of
fertility preservation treatment and the severity of infertility as a disease, but also open the door for more discussions between patients
and providers about fertility preservation treatment. Furthermore, a
mandate would allow greater access by patients from lower socioeconomic statuses, patients without insurance, and patients who do not
have advocates to help them secure funding for this technology.
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